Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Fluctuating Methylation-based ctDNA Detection in NSCLC Surveillance: Implications for Serial Monitoring and Specificity

In this retrospective cohort of 85 patients who underwent lung resection or stereotactic body radiation therapy for NSCLC and then a commercially available methylation-based ctDNA test (Guardant Reveal, named in the methods), 17 (20%) had at least one positive result. Ten of those 17 patients (59%) later tested negative, and 11 (65%) had a ctDNA tumor fraction near the limit of detection without radiographic recurrence; three patients with ctDNA fractions above the limit of detection had confirmed recurrence, and none in the ctDNA-negative group had disease recurrence. The authors conclude that isolated low-level positivity may not warrant clinical action and that serial results should be interpreted as trends rather than from a single test.

JTO Clinical and Research ReportsPubMed 43036776DOI 10.1016/j.jtocrr.2026.101081